BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marot A, Singal AK, Moreno C, Deltenre P. Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials. JHEP Rep 2020;2:100139. [PMID: 32775975 DOI: 10.1016/j.jhepr.2020.100139] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, Donovan JA, Alcorn JM, Chao DC, Asghar A, Morgan TR; Southern California Alcoholic Hepatitis (SCAH) Consortium. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis. EClinicalMedicine 2022;54:101689. [PMID: 36267499 DOI: 10.1016/j.eclinm.2022.101689] [Reference Citation Analysis]
2 Ha Y, Jeong I, Kim TH. Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives. Biomedicines 2022;10:2530. [PMID: 36289791 DOI: 10.3390/biomedicines10102530] [Reference Citation Analysis]
3 Lu H. Narrative Review: Glucocorticoids in Alcoholic Hepatitis—Benefits, Side Effects, and Mechanisms. JoX 2022;12:266-288. [DOI: 10.3390/jox12040019] [Reference Citation Analysis]
4 Virovic-Jukic L, Ljubas D, Stojsavljevic-Shapeski S, Ljubičić N, Filipec Kanizaj T, Mikolasevic I, Grgurevic I. Liver regeneration as treatment target for severe alcoholic hepatitis. World J Gastroenterol 2022; 28(32): 4557-4573 [DOI: 10.3748/wjg.v28.i32.4557] [Reference Citation Analysis]
5 Cho Y, Joshi R, Lowe P, Copeland C, Ribeiro M, Morel C, Catalano D, Szabo G. Granulocyte colony-stimulating factor attenuates liver damage by M2 macrophage polarization and hepatocyte proliferation in alcoholic hepatitis in mice. Hepatol Commun 2022. [PMID: 35997009 DOI: 10.1002/hep4.1925] [Reference Citation Analysis]
6 Nevens F, van der Merwe S. Mesenchymal Stem Cell Transplantation in Liver Diseases. Semin Liver Dis 2022;42:283-92. [PMID: 36049782 DOI: 10.1055/s-0042-1755328] [Reference Citation Analysis]
7 Abbas N, Rajoriya N, Elsharkawy AM, Chauhan A. Acute-on-chronic liver failure (ACLF) in 2022: have novel treatment paradigms already arrived? Expert Rev Gastroenterol Hepatol 2022. [PMID: 35786130 DOI: 10.1080/17474124.2022.2097070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Szabo G, Thursz M, Shah VH. Therapeutic advances in alcohol-associated hepatitis. J Hepatol 2022;76:1279-90. [PMID: 35589250 DOI: 10.1016/j.jhep.2022.03.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Singal AK, Kwo P, Kwong A, Liangpunsakul S, Louvet A, Mandrekar P, McClain C, Mellinger J, Szabo G, Terrault N, Thursz M, Winder GS, Kim WR, Shah VH. Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease. Hepatology 2022;75:1026-37. [PMID: 34496071 DOI: 10.1002/hep.32143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jindal A. Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look! Hepatology 2022;75:766-7. [PMID: 34890062 DOI: 10.1002/hep.32276] [Reference Citation Analysis]
11 Trebicka J, Louvet A, Arroyo V, Jalan R, Shah VH, Moreau R. Severe alcoholic hepatitis as precipitant for organ failure and ACLF. Z Gastroenterol 2022;60:67-76. [PMID: 35042255 DOI: 10.1055/a-1713-3796] [Reference Citation Analysis]
12 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Gougol A, Clemente-Sanchez A, Argemi J, Bataller R. Alcoholic Hepatitis. Clin Liver Dis (Hoboken) 2021;18:90-5. [PMID: 34584675 DOI: 10.1002/cld.1092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Jindal A, Jagdish RK, Kumar A. Hepatic Regeneration in Cirrhosis. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.08.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Van Melkebeke L, Korf H, Tsochatzis EA, van der Merwe S, Nevens F, Verbeek J. Treatment of severe alcoholic hepatitis: A systematic review. Curr Opin Pharmacol 2021;60:91-101. [PMID: 34365226 DOI: 10.1016/j.coph.2021.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Engelmann C, Herber A, Franke A, Bruns T, Schiefke I, Zipprich A, Zeuzem S, Goeser T, Canbay A, Berg C, Trebicka J, Uschner FE, Chang J, Mueller T, Aehling N, Schmelzle M, Splith K, Lammert F, Lange CM, Sarrazin C, Trautwein C, Manns M, Häussinger D, Pfeiffenberger J, Galle PR, Schmiedeknecht A, Berg T. Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). J Hepatol 2021:S0168-8278(21)01963-2. [PMID: 34364917 DOI: 10.1016/j.jhep.2021.07.033] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
17 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
18 Maddur H. Current Therapies for Alcohol-Associated Hepatitis. Clin Liver Dis 2021;25:595-602. [PMID: 34229842 DOI: 10.1016/j.cld.2021.03.005] [Reference Citation Analysis]
19 Engelmann C, Martino VD, Kerbert AJC, Weil-Verhoeven D, Aehling NF, Herber A, Thévenot T, Berg T. The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure. Semin Liver Dis 2021;41:298-307. [PMID: 33992029 DOI: 10.1055/s-0041-1723034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
20 Liu SY, Tsai IT, Hsu YC. Alcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives. Int J Mol Sci 2021;22:5170. [PMID: 34068269 DOI: 10.3390/ijms22105170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
21 Wang H, Mehal W, Nagy LE, Rotman Y. Immunological mechanisms and therapeutic targets of fatty liver diseases. Cell Mol Immunol 2021;18:73-91. [PMID: 33268887 DOI: 10.1038/s41423-020-00579-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
22 Chen Y, Luo Y, Wu F, Liao N, Shi Q, Mao D. Traditional Chinese medicine enema for acute chronic liver failure: A protocol of systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore) 2020;99:e22585. [PMID: 33031310 DOI: 10.1097/MD.0000000000022585] [Reference Citation Analysis]
23 Sarin SK, Sharma S. Predictors of steroid non-response and new approaches in severe alcoholic hepatitis. Clin Mol Hepatol 2020;26:639-51. [PMID: 33053936 DOI: 10.3350/cmh.2020.0196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Schwabe RF. Regenerating research and life. JHEP Rep 2020;2:100172. [PMID: 32838248 DOI: 10.1016/j.jhepr.2020.100172] [Reference Citation Analysis]